- Home
- RXRX
as of 12-12-2025 3:43pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.5B | IPO Year: | 2021 |
| Target Price: | $7.25 | AVG Volume (30 days): | 21.7M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.79 - $12.36 | Next Earning Date: | 11-05-2025 |
| Revenue: | $43,689,000 | Revenue Growth: | -32.98% |
| Revenue Growth (this year): | 7.79% | Revenue Growth (next year): | 27.32% |
AI-Powered RXRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
Director
Avg Cost/Share
$4.37
Shares
220,000
Total Value
$961,400.00
Owned After
6,869,863
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.16
Shares
40,000
Total Value
$166,400.00
Owned After
913,839
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.21
Shares
40,000
Total Value
$208,400.00
Owned After
913,839
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Borgeson Blake | RXRX | Director | Dec 2, 2025 | Sell | $4.37 | 220,000 | $961,400.00 | 6,869,863 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 19, 2025 | Sell | $4.16 | 40,000 | $166,400.00 | 913,839 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 4, 2025 | Sell | $5.21 | 40,000 | $208,400.00 | 913,839 |
Compare RXRX vs Leading Stocks
See how RXRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.